Apo Nitrofurantoine

Quick links

Choose a section

Quick links to important sections

Advertisements

Apo Nitrofurantoine

Advertisements
Advertisements

Overview of Apo Nitrofurantoine

Property Description
Active ingredient Nitrofurantoin
Form Tablets and Capsules (Oral)
Pharmacological class Antibiotic, Urinary Tract Anti-infective
Common use Addressing susceptible bacterial infections
Origin Synthetic nitrofuran derivative

What is the Identity and Pharmacological Class of Apo-Nitrofurantoin?

Apo-Nitrofurantoin is the trade name for a medicine containing the active substance Nitrofurantoin, which is primarily classified as an antibiotic and a synthetic nitrofuran derivative.

This designation places the drug within the family of anti-infective agents specifically focused on the urinary tract. Nitrofurantoin functions as an antibiotic to stop the growth of bacteria. Its specialized role involves managing infections confined to the lower urinary system. The medication is a chemically produced compound, not derived from a natural source, and is supplied as a single-ingredient product.


Composition and Available Dosage Forms

Nitrofurantoin is the sole therapeutic agent, combined with solid pharmaceutical excipients necessary for stability and manufacturing. Apo-Nitrofurantoin is prepared for oral administration, commonly available in solid dosage forms such as tablets and capsules. These capsules often feature different particle sizes, such as a macrocrystalline formulation, which influences the rate at which the active substance is released and absorbed in the digestive tract.

The macrocrystalline formulation is designed to provide a slower absorption rate. This distinction in physical form is crucial for optimizing drug concentration at the site of action, which is a key aspect of the drug's effectiveness.


What is the General Therapeutic Purpose of Nitrofurantoin?

The general therapeutic purpose of this medication is to achieve the elimination of susceptible pathogens that cause infections localized within the urinary system, such as those that define uncomplicated cystitis. Nitrofurantoin is characterized as a bactericidal agent, meaning it actively kills the targeted bacteria.

Its primary functional advantage is its selective concentration: the kidneys rapidly filter and excrete the drug into the urine, ensuring high levels of the active antibiotic are present directly in the urinary tract where the infection resides, providing effective clearance of the causative organisms. This localized action is a key differentiating feature that informs its use in specific patient groups.

Regulatory References

  1. MedlinePlus Drug Information
  2. National registers of authorised medicines (EMA)
Advertisements

What side effects are possible with Apo Nitrofurantoine?

Possible Side Effects and Safety Information

Adverse reactions associated with this medication, which contains Nitrofurantoin, are categorized by the systems and organs they affect, as detailed in official regulatory documents. While many effects are classified with an Incidence Not Known frequency, certain serious reactions are officially described in safety labeling.

Key Regulatory Safety Classifications

Organ System-Specific Reactions The medication's safety profile includes potential effects on the respiratory system (e.g., acute and chronic pulmonary reactions), hepatobiliary system (e.g., hepatitis, hepatic necrosis), nervous system (e.g., peripheral neuropathy), and blood and lymphatic system (e.g., hemolytic anemia). Common expected reactions frequently listed in labeling include nausea, vomiting, anorexia, and the harmless brown or yellow discoloration of urine.

Serious Adverse Reactions Official regulatory documents cite several serious reactions, including potentially fatal outcomes associated with chronic active hepatitis and hepatic necrosis. The labeling also addresses severe or irreversible peripheral neuropathy and notes that certain pulmonary reactions have been cited as a contributing cause of death. Immediate drug discontinuation is required if unexplained pulmonary, hepatic, or neurological syndromes occur.

Population and Exposure Constraints Safety is formally restricted by several contraindications. The medication is contraindicated in patients with significant renal impairment (e.g., creatinine clearance under 60 mL per minute) and in pregnant patients at term (38–42 weeks gestation). Furthermore, the safety profile notes that acute pulmonary reactions typically appear within the first week of treatment, whereas chronic pulmonary reactions are usually associated with therapy lasting six months or longer.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

This section describes the officially documented manifestations and required emergency actions for an overdose of Nitrofurantoin, based strictly on government regulatory documents.

Overdose Scope

Domain Official Regulatory Statement
Documented overdose presentations Gastric irritation, nausea, and vomiting are the officially listed acute signs associated with overdosage.
Physiological systems affected Severe toxicities documented in regulatory labeling affect the neurological (peripheral neuropathy), hepatic (hepatitis/necrosis), and pulmonary systems (acute/chronic reactions), with reported fatal outcomes.
Population-specific overdose notes Patients with significant renal impairment (creatinine clearance under 60 mL/ minute) are noted to have an increased risk of toxicity due to impaired drug excretion.
When immediate medical help is required Seek immediate medical attention for overdosage. Treatment must be immediately withdrawn if the patient exhibits signs of severe systemic syndromes, such as pulmonary or hepatic toxicity.

Overdose Classifications (High-level)

Classification Official Regulatory Statement
Severity classification Severity is defined by the manifestation of potentially severe or irreversible systemic toxicities.
Overdose-context constraints No known specific antidote is documented, requiring close monitoring of full blood count, liver function, and pulmonary function tests.

Resulting Overdose Structure

Official guidance mandates that management relies on symptomatic and supportive measures, which may include gastric lavage or haemodialysis for recent ingestion, along with maintaining a high fluid intake to promote drug excretion. The official overdose profile emphasizes urgent medical attention due to the risk of severe systemic damage.

Advertisements

Therapeutic Uses of Apo Nitrofurantoine

What Apo-Nitrofurantoine Treats: Main Uses and Benefits

Apo-Nitrofurantoin is generally used within the therapeutic domain of urinary tract anti-infectives. This medication is applicable for conditions involving bacterial infections localized to the lower urinary system, and is commonly applied in clinical settings that involve acute, uncomplicated cystitis and other lower urinary tract infections caused by susceptible bacteria.

Symptom Management and Therapeutic Support

Its therapeutic role is relevant for managing the infection by addressing the susceptible bacteria. Used within this therapeutic context, the medication is relevant for easing symptoms related to inflammatory or irritative states in the lower urinary system. This may assist with easing painful urination (dysuria), as well as symptoms of increased physiological activity such as urinary frequency and urgency.

Quick Fact: Voiding Discomfort is commonly managed within this therapeutic domain.

The drug is also applied in scenarios where prevention of recurrent infections is appropriate for patient groups who frequently experience recurrent infections, contributing to managing these conditions characterized by episodic manifestations.

This therapeutic support generally assists with easing the overall symptom burden associated with bacterial lower urinary tract distress.

Advertisements

Eligibility and Restrictions for Use

Official Eligibility Profile

The eligibility for Apo-Nitrofurantoine (Nitrofurantoin) is strictly defined by regulatory documents, outlining populations for whom the medicine is permitted, restricted, or absolutely prohibited.

Classification Population/Condition
Allowed Adults and pediatric patients 1 month of age and older with sufficient renal function.
Contraindicated Patients with anuria, oliguria, or renal impairment (creatinine clearance under 60 mL per minute).
Contraindicated Neonates under one month of age; pregnant patients at term (38–42 weeks gestation, labor, or delivery).
Contraindicated Patients with known hypersensitivity to the drug, a history of nitrofurantoin-induced cholestatic jaundice/hepatic dysfunction, or G6PD deficiency.

Age and Physiological Status Rules

Use is prohibited in infants under one month old and in pregnant patients at term due to the risk of hemolytic anemia in the newborn. While older adults are generally eligible, official labeling advises caution due to the higher likelihood of reduced renal function; the renal impairment contraindication is absolute regardless of age. For breastfeeding, use is not recommended when nursing an infant under one month of age or an infant with G6PD deficiency.

Eligibility Restrictions

The medicine is not indicated for the treatment of upper urinary tract infections, such as pyelonephritis. Patients with existing conditions like diabetes mellitus, severe anemia, or Vitamin B deficiency are also noted in official documents as requiring special consideration due to an increased risk of toxicity.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory information for Apo Nitrofurantoine interactions primarily identifies substances that alter the medicine's bioavailability or interfere with its renal excretion.

Interaction Scope

Category Description / Entity
Medicinal product categories with documented interactions Uricosuric drugs, Quinolone antimicrobials, Antacids, Oral live vaccines, Urine alkalizers.
Specific interacting medicines (if explicitly listed) Probenecid, Sulfinpyrazone, Magnesium Trisilicate Antacids.
Mechanistic basis of interactions (only if stated in label) Inhibition of renal tubular secretion (Transporter-mediated pharmacokinetic interaction); Reduction of absorption (Pharmacokinetic interaction); Anti-bacterial antagonism (Pharmacodynamic interaction).
Timing-based interaction rules (if applicable) Co-administration of Magnesium Trisilicate antacids is restricted due to reduced absorption. Administration with food officially increases absorption.

Interaction Classifications (High-Level)

Classification Description / Entity
Interaction severity classification (as defined in official documents) Contra-administration restriction (Magnesium Trisilicate Antacids); Clinically significant (Uricosuric drugs); Antagonism noted (Quinolones).
Population-specific interaction notes (if applicable) Reduced excretion in impaired renal function (e.g., eGFR < 45 mL/min/1.73m^2) results in systemic accumulation and loss of therapeutic urinary concentration.

Resulting interaction structure

Official regulatory documents state that Probenecid and Sulfinpyrazone inhibit the renal tubular secretion of Nitrofurantoin. This transporter-mediated interaction elevates serum levels while simultaneously decreasing the necessary drug concentration in the urine. Magnesium Trisilicate antacids are subject to a contra-administration restriction because they officially reduce both the rate and extent of Nitrofurantoin absorption. Administration with food is documented to increase the medicine's bioavailability. Furthermore, Quinolone antimicrobials have demonstrated antagonism in vitro with Nitrofurantoin. The medicine may also cause false-positive results in certain tests for glucose in the urine.

Advertisements

Mechanism of Action

Drug Bioactivation by Bacterial Enzymes

Apo-Nitrofurantoin acts as an inactive prodrug that is converted into its potent form exclusively by nitroreductase enzymes residing within susceptible bacteria. This targeted intracellular bioactivation is the essential first step. This process restricts the drug's bioactivation mechanism to organisms possessing the necessary bacterial enzymes.

Multi-Target Cellular Disruption

Once activated, the highly reactive intermediates rapidly engage in non-specific covalent binding with multiple essential bacterial components, including DNA, RNA, and proteins necessary for energy production. This simultaneous attack on genetic and metabolic pathways blocks replication and results in bacterial cell death (a bactericidal physiological effect).

Localization via Rapid Renal Clearance

The mechanism's concentration is determined by the rapid renal excretion of the drug into the urine, leading to exceptionally high concentrations at the site of its intended action. This physiological localization ensures the mechanism is activated at high concentrations within the urinary tract environment.

Advertisements

Dosage and Administration Information

How to Use Apo Nitrofurantoine

The administration of nitrofurantoin is exclusively through the oral route, available in forms such as capsules and oral suspension. A core instruction for use is that all formulations must be administered with food or milk. This practice is to enhance drug absorption and minimize potential gastrointestinal discomfort.


Standard Dosing Regimens and Frequency

Use of the medication is structured around two primary patterns: treatment of acute episodes and long-term prophylaxis.

  • Acute Treatment: The standard dosage is typically 50 mg to 100 mg per dose. The macrocrystalline or suspension formulations are generally taken four times per day (q.i.d.). Dual-release formulations are commonly administered as 100 mg taken twice daily (b.i.d.). The usual course duration for acute uncomplicated infection is 7 days.
  • Suppression/Prophylaxis: For long-term prevention of recurrence, a reduced dose of 50 mg to 100 mg is prescribed for administration once daily, often taken at bedtime.

Specific Administration Instructions

Administration requires specific handling procedures based on the form. The oral suspension must be shaken vigorously before each dose to ensure the active ingredient is properly dispersed. Dual-release capsules must be swallowed whole and should not be crushed or opened. The use of nitrofurantoin is restricted by kidney function, which serves as a precondition for administration. Additionally, if a dose is missed, it should be taken as soon as it is remembered, unless the next scheduled dose is imminent.

Advertisements

Recent Clinical Evidence

Evidence for Use in Acute, Uncomplicated Lower Urinary Tract Infections

Research exploring this medication in the context of acute, uncomplicated lower urinary tract infections (UTIs), such as cystitis, includes substantial evidence derived from Randomized Controlled Trials (RCTs) and Systematic Reviews. The research explored populations predominantly including adult women (non-pregnant), and separate studies examined specific populations like older adult patients.

The studies monitored key outcomes, including clinical resolution (tracking symptom change) and microbiological clearance (tracking bacterial elimination). Trials explored the medicine by comparing it against placebo or other standard antibiotics commonly used for the same condition. A limitation is that some foundational studies used in regulatory submissions were conducted decades ago, and research suggests that outcomes may be diminished when very short (e.g., 3-day) treatment courses are studied.

Evidence for Prevention of Recurrent Urinary Tract Infections

The medicine was studied for its role in research exploring the prevention of UTIs in patient groups who experience recurrent infections. Randomized Controlled Trials and Observational Studies monitored the frequency of recurrence and the time elapsed until a relapse occurred. However, the research for long-term prevention is noted as less extensive and more heterogeneous in study design compared to the evidence for acute treatment.

Research in Special Populations and Limitations

Studies examined specific populations, including select pediatric patients (girls) and those with co-existing conditions such as diabetes. The overall evidence landscape shows that comparative evidence is lacking for some of the most current treatments, and data for certain groups, such as men with UTIs, often remain insufficient in major randomized trials. These factors mean that while the medicine was studied extensively, research does not determine whether an individual will respond similarly; findings describe group patterns, not personal outcomes.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Apo Nitrofurantoine (FAQ)


Q: Why is Apo Nitrofurantoine sometimes called Macrobid or Macrodantin?

Apo Nitrofurantoine contains the active ingredient called nitrofurantoin. According to official regulatory documents, this active substance is marketed under various trade names globally, including Macrobid, Macrodantin, and Furadantin.


Q: Is there a link between Apo Nitrofurantoine and feeling dizzy or drowsy?

Official safety information reports that dizziness, lightheadedness, vertigo, and drowsiness are potential side effects associated with the use of nitrofurantoin. Official patient information advises caution regarding activities requiring concentration, such as driving or operating machinery, until the individual is aware of how the medicine may affect them.


Q: Is it normal to feel a bit nauseous when starting Apo Nitrofurantoine?

Nausea is classified in regulatory safety documents as a common gastrointestinal side effect associated with taking the medication. Regulatory documents describe taking the medicine with food or milk as the practice mandated to enhance absorption and minimize potential gastrointestinal discomfort.


Q: Can Apo Nitrofurantoine cause changes in blood test results?

Regulatory documents state that nitrofurantoin may cause false-positive results in certain tests used to measure glucose (sugar) in the urine. Furthermore, the medicine is associated with a risk of hemolytic anemia (a condition where red blood cells are destroyed) in specific, susceptible patients.


Q: Can people who are allergic to penicillin still take Apo Nitrofurantoine?

Official labeling lists a known hypersensitivity (allergy) to nitrofurantoin itself as a strict reason not to use the drug. Official regulatory documents do not list cross-reactivity with the penicillin class of antibiotics in the contraindications or warnings sections.


Q: What happens if a dose of Apo Nitrofurantoine is missed?

Regulatory guidance instructs that if a dose is missed, it should be taken as soon as it is remembered. However, if the time for the next scheduled dose is imminent, the missed dose should be skipped entirely, and the regular dosing schedule should be continued. The guidance specifies that a double dose should not be taken to compensate for a missed dose.


Q: Can this medication cause nerve problems like tingling or numbness?

Official regulatory documents describe the risk of peripheral neuropathy. This condition, which may become severe or irreversible, involves nerve damage, and symptoms reported can include sensory changes such as tingling or numbness.


Q: Can Apo Nitrofurantoine be taken with pain relievers like ibuprofen or acetaminophen?

Official regulatory drug interaction documents do not list a pharmacokinetic interaction between nitrofurantoin and common non-prescription pain relievers such as ibuprofen or acetaminophen.


Q: Is it true that the effectiveness of Apo Nitrofurantoine is not affected by antibiotic resistance as much as other drugs?

Research evidence has examined the durability of nitrofurantoin against resistance, noting that its multi-target mechanism of action against bacteria contributes to a low rate of resistance development.


Q: What specific pre-existing conditions (besides kidney issues) might make Apo Nitrofurantoine unsuitable?

The medicine is contraindicated in patients with G6PD deficiency and a history of nitrofurantoin-induced cholestatic jaundice or hepatic dysfunction. Official labeling also notes that special caution is required for patients with severe anemia, diabetes mellitus, and vitamin B deficiency due to an increased risk of toxicity.


Q: Why are people with G6PD deficiency cautioned against using Apo Nitrofurantoine?

Official regulatory warnings state that patients with Glucose-6-phosphate dehydrogenase (G6PD) deficiency have a specific risk of developing hemolytic anemia (the premature destruction of red blood cells) when taking nitrofurantoin. This is why this condition is listed as a contraindication.


Q: How does the time-release (macro-crystal) formulation of Apo Nitrofurantoine work?

Official documentation describes the macrocrystalline formulation as being designed to provide a slower rate of absorption from the digestive tract. This slower release is a key part of optimizing the drug's concentration in the urinary system, which is the site of the infection.


Q: Does taking Apo Nitrofurantoine cause vaginal yeast infections?

The official warnings state that the use of nitrofurantoin may result in the possible overgrowth of nonsusceptible organisms, such as Candida species.


Q: What information is available about the use of Apo Nitrofurantoine during breastfeeding?

Official labeling notes that the medicine is distributed into breast milk. The official guidance involves either discontinuing nursing or discontinuing the drug, particularly when nursing an infant under one month of age or an infant with G6PD deficiency.


Q: Does Apo Nitrofurantoine interact with vaccines?

Official regulatory documents specifically list a potential drug interaction with oral live vaccines, such as the live cholera vaccine.


Q: Does the medicine come in different strengths?

Yes, the active ingredient, nitrofurantoin, is available for oral use in multiple dosage strengths. These typically include 25 mg, 50 mg, and 100 mg capsules or tablets, depending on the specific formulation being used.


Q: Are there any known interactions between Apo Nitrofurantoine and herbal supplements?

Regulatory caution is given for the use of unstudied complementary or herbal products alongside prescription medicines, as their safety and interaction potential have not been formally established.


Q: How long does the FDA/regulatory bodies recommend using this drug?

For acute uncomplicated infections, the course duration described in regulatory prescribing information is typically 7 days. The course for long-term prevention is noted as up to six months. Use beyond this period requires specific caution due to the risk of chronic side effects.


Q: Is Apo Nitrofurantoine available over the counter in some places?

In most countries, this medication is classified as a prescription medicine and is available only with authorization from a licensed healthcare provider after a medical assessment.


Q: Does this antibiotic have an effect on blood sugar levels?

Available evidence does not indicate a direct effect of nitrofurantoin on blood sugar levels. However, official labeling notes that patients with pre-existing conditions like diabetes mellitus require special consideration due to a heightened risk of drug toxicity.


Q: Can Apo Nitrofurantoine be used by individuals with chronic liver disease?

The use of nitrofurantoin is addressed in official documents due to the potential for the medicine to cause hepatotoxicity (liver damage). Contraindications include a history of nitrofurantoin-induced hepatic dysfunction, and caution is noted for chronic liver disease in general.


Q: How long does Apo Nitrofurantoine stay in the body after the last dose?

The medicine is rapidly eliminated from the bloodstream. Official prescribing information indicates that the half-life in the plasma is short, typically ranging from 20 to 60 minutes. This rapid clearance helps ensure the medicine concentrates effectively in the urinary tract.

Advertisements

How should Apo Nitrofurantoine be stored and disposed of?

How to Store and Dispose of Apo-Nitrofurantoin

Official regulatory guidelines strictly define the necessary conditions for storing and disposing of Apo-Nitrofurantoin (nitrofurantoin) to maintain its stability and ensure safety.

Storage Conditions

Apo-Nitrofurantoin capsules must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be protected from freezing, excess heat, and moisture. To preserve product integrity, the medication should remain in its original container and be kept tightly closed.

Furthermore, all forms of this medication must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired medicinal product and waste material must be disposed of in accordance with local requirements. The preferred method for discarding the medication is by utilizing a formal drug take-back program or an approved mail-back system, which helps prevent accidental ingestion or environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Apo Nitrofurantoine found in:

A-Z Index: